-
Je něco špatně v tomto záznamu ?
Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration--a comparison between 2 citrate modalities and unfractionated heparin
M. Balik, M. Zakharchenko, P. Leden, M. Otahal, J. Hruby, F. Polak, K. Rusinova, Z. Stach, M. Tokarik, J. Vavrova, A. Jabor, HM. Oudemans-van Straaten,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie, klinické zkoušky kontrolované, časopisecké články, práce podpořená grantem
Grantová podpora
NS10014
MZ0
CEP - Centrální evidence projektů
NLK
ProQuest Central
od 2003-03-01 do Před 2 měsíci
Medline Complete (EBSCOhost)
od 2012-10-01 do 2015-08-31
Nursing & Allied Health Database (ProQuest)
od 2003-03-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2003-03-01 do Před 2 měsíci
- MeSH
- akutní poškození ledvin terapie MeSH
- antikoagulancia škodlivé účinky ekonomika farmakologie MeSH
- citráty škodlivé účinky ekonomika farmakologie MeSH
- dialyzační roztoky škodlivé účinky ekonomika farmakologie MeSH
- energetický metabolismus účinky léků MeSH
- energetický příjem účinky léků MeSH
- hemodiafiltrace škodlivé účinky ekonomika metody MeSH
- heparin škodlivé účinky ekonomika farmakologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- náklady na zdravotní péči MeSH
- prospektivní studie MeSH
- vodní a elektrolytová nerovnováha etiologie prevence a kontrola MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky kontrolované MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
PURPOSE: To determine bioenergetic gain of 2 different citrate anticoagulated continuous hemodiafiltration (CVVHDF) modalities and a heparin modality. MATERIALS AND METHODS: We compared the bio-energetic gain of citrate, glucose and lactate between 29 patients receiving 2.2% acid-citrate-dextrose with calcium-containing lactate-buffered solutions (ACD/Ca(plus)/lactate), 34 on 4% trisodium citrate with calcium-free low-bicarbonate buffered fluids (TSC/Ca(min)/bicarbonate), and 18 on heparin with lactate buffering (Hep/lactate). RESULTS: While delivered CVVHDF dose was about 2000 mL/h, total bioenergetic gain was 262 kJ/h (IQR 230-284) with ACD/Ca(plus)/lactate, 20 kJ/h (8-25) with TSC/Ca(min)/bicarbonate (P < .01) and 60 kJ/h (52-76) with Hep/lactate. Median patient delivery of citrate was 31.2 mmol/h (25-34.7) in ACD/Ca(plus)/lactate versus 14.8 mmol/h (12.4-19.1) in TSC/Ca(min)/bicarbonate groups (P < .01). Median delivery of glucose was 36.8 mmol/h (29.9-43) in ACD/Ca(plus)/lactate, and of lactate 52.5 mmol/h (49.2-59.1) in ACD/Ca(plus)/lactate and 56.1 mmol/h (49.6-64.2) in Hep/lactate groups. The higher energy delivery with ACD/Ca(plus)/lactate was partially due to the higher blood flow used in this modality and the calcium-containing dialysate. CONCLUSIONS: The bioenergetic gain of CVVHDF comes from glucose (in ACD), lactate and citrate. The amount substantially differs between modalities despite a similar CVVHDF dose and is unacceptably high when using ACD with calcium-containing lactate-buffered solutions and a higher blood flow. When calculating nutritional needs, we should account for the energy delivered by CVVHDF.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024318
- 003
- CZ-PrNML
- 005
- 20230803073426.0
- 007
- ta
- 008
- 130703s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jcrc.2012.06.003 $2 doi
- 035 __
- $a (PubMed)22951019
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Balík, Martin $u Department of Anaesthesiology and Intensive Care, First Faculty of Medicine, Charles University and General University Hospital, U nemocnice 2, Prague 2, 120 00, Czech Republic. martin.balik@post.cz $7 xx0075661
- 245 10
- $a Bioenergetic gain of citrate anticoagulated continuous hemodiafiltration--a comparison between 2 citrate modalities and unfractionated heparin / $c M. Balik, M. Zakharchenko, P. Leden, M. Otahal, J. Hruby, F. Polak, K. Rusinova, Z. Stach, M. Tokarik, J. Vavrova, A. Jabor, HM. Oudemans-van Straaten,
- 520 9_
- $a PURPOSE: To determine bioenergetic gain of 2 different citrate anticoagulated continuous hemodiafiltration (CVVHDF) modalities and a heparin modality. MATERIALS AND METHODS: We compared the bio-energetic gain of citrate, glucose and lactate between 29 patients receiving 2.2% acid-citrate-dextrose with calcium-containing lactate-buffered solutions (ACD/Ca(plus)/lactate), 34 on 4% trisodium citrate with calcium-free low-bicarbonate buffered fluids (TSC/Ca(min)/bicarbonate), and 18 on heparin with lactate buffering (Hep/lactate). RESULTS: While delivered CVVHDF dose was about 2000 mL/h, total bioenergetic gain was 262 kJ/h (IQR 230-284) with ACD/Ca(plus)/lactate, 20 kJ/h (8-25) with TSC/Ca(min)/bicarbonate (P < .01) and 60 kJ/h (52-76) with Hep/lactate. Median patient delivery of citrate was 31.2 mmol/h (25-34.7) in ACD/Ca(plus)/lactate versus 14.8 mmol/h (12.4-19.1) in TSC/Ca(min)/bicarbonate groups (P < .01). Median delivery of glucose was 36.8 mmol/h (29.9-43) in ACD/Ca(plus)/lactate, and of lactate 52.5 mmol/h (49.2-59.1) in ACD/Ca(plus)/lactate and 56.1 mmol/h (49.6-64.2) in Hep/lactate groups. The higher energy delivery with ACD/Ca(plus)/lactate was partially due to the higher blood flow used in this modality and the calcium-containing dialysate. CONCLUSIONS: The bioenergetic gain of CVVHDF comes from glucose (in ACD), lactate and citrate. The amount substantially differs between modalities despite a similar CVVHDF dose and is unacceptably high when using ACD with calcium-containing lactate-buffered solutions and a higher blood flow. When calculating nutritional needs, we should account for the energy delivered by CVVHDF.
- 650 _2
- $a akutní poškození ledvin $x terapie $7 D058186
- 650 _2
- $a antikoagulancia $x škodlivé účinky $x ekonomika $x farmakologie $7 D000925
- 650 _2
- $a citráty $x škodlivé účinky $x ekonomika $x farmakologie $7 D002951
- 650 _2
- $a dialyzační roztoky $x škodlivé účinky $x ekonomika $x farmakologie $7 D015314
- 650 _2
- $a energetický příjem $x účinky léků $7 D002149
- 650 _2
- $a energetický metabolismus $x účinky léků $7 D004734
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a náklady na zdravotní péči $7 D017048
- 650 _2
- $a hemodiafiltrace $x škodlivé účinky $x ekonomika $x metody $7 D017583
- 650 _2
- $a heparin $x škodlivé účinky $x ekonomika $x farmakologie $7 D006493
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a vodní a elektrolytová nerovnováha $x etiologie $x prevence a kontrola $7 D014883
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a klinické zkoušky kontrolované $7 D018848
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zakharchenko, Mikhailo $u - $7 xx0304761
- 700 1_
- $a Leden, Pavel $u -
- 700 1_
- $a Otahal, Michal $u -
- 700 1_
- $a Hruby, Jan $u -
- 700 1_
- $a Polak, Ferdinand $u -
- 700 1_
- $a Rusinova, Katerina $u -
- 700 1_
- $a Stach, Zdenek $u -
- 700 1_
- $a Tokarik, Monika $u -
- 700 1_
- $a Vavrova, Jaroslava $u -
- 700 1_
- $a Jabor, Antonin $u -
- 700 1_
- $a Oudemans-van Straaten, Heleen M $u -
- 773 0_
- $w MED00002627 $t Journal of critical care $x 1557-8615 $g Roč. 28, č. 1 (2013), s. 87-95
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22951019 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20230803073421 $b ABA008
- 999 __
- $a ok $b bmc $g 987998 $s 822698
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 28 $c 1 $d 87-95 $i 1557-8615 $m Journal of critical care $n J Crit Care $x MED00002627
- GRA __
- $a NS10014 $p MZ0
- LZP __
- $a Pubmed-20130703
